BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Kalypsys, Inc. Announces Small Molecule Research Collaboration With Alcon, Inc. (ACL)


1/4/2006 10:39:33 AM

SAN DIEGO, Jan. 4 /PRNewswire/ -- Kalypsys, Inc. announced today that it has entered into a collaboration agreement with the objective of delivering ophthalmic drug candidates for development and commercialization by Alcon Research, Ltd. and Alcon Manufacturing, Ltd., which are affiliates of Alcon, Inc., the world's leading eye care company.

Under terms of a four year agreement, Kalypsys will receive an access fee, research support, and milestone payments. In addition, Kalypsys will receive royalty payments on net sales of commercial products. An additional component of the agreement gives Alcon preferred partnering access to compounds from Kalypsys programs.

"We are pleased that Alcon has partnered with Kalypsys to gain access to our technology, capabilities, and approach to drug discovery," commented John McKearn, President and CEO of Kalypsys. "Moreover, Alcon's access to Kalypsys programs amplifies the value of our pipeline and establishes a relationship to partner Kalypsys compounds with the premiere company in ophthalmology. We intend to enter into a limited number of important alliances in other therapeutic fields in the next 12-18 months and we are delighted that Alcon represents the first of our expected agreements."

In the collaboration, Kalypsys will use its uHTS technology and chemical library to identify and profile active molecules against collaboration targets. Kalypsys will also apply its medicinal chemistry and other drug discovery capabilities in partnership with Alcon's research capabilities and expertise in ophthalmology. Alcon will be responsible for all development, manufacturing, and commercialization of products.

"In our view, Kalypsys offers a unique combination of an experienced management team and world-class pharmaceutical technology to create a powerful drug discovery engine that we envision will help grow and advance our expected pipeline of novel and important drugs to treat diseases of the eye," said Martin B. Wax M.D., Alcon's Vice President of R&D and head of Ophthalmology Discovery Research.

About Kalypsys

Kalypsys is a privately owned San Diego small molecule drug discovery and development company that is applying its integrated drug discovery infrastructure, suite of ultra-high throughput lead discovery technologies, and seasoned team of scientists to advance its pipeline into clinical development. Kalypsys uses its technologies, integrated capabilities and sizeable drug-like compound collection to improve the drug discovery research process and generate a robust pipeline for itself and its partners. Kalypsys' mission is to participate in targeted commercial opportunities by building a sustainable drug candidate pipeline from target to proof of efficacy and safety in the clinic with unmatched speed, efficiency, and success rates. For more information on Kalypsys, please visit http://www.kalypsys.com.

Contacts: Kalypsys, Inc: Noonan Russo: John Delyani, Ph.D. Holli Kolkey Director, Business Development Phone: +1.858.546.4811 Phone: +1.858.754.3434 holli.kolkey@eurorscg.com

Kalypsys, Inc.

CONTACT: John Delyani, Ph.D., Director, Business Development, Kalypsys,Inc., +1-858-754-3434; or Holli Kolkey, Noonan Russo, +1-858-546-4811,holli.kolkey@eurorscg.com


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->